. 2021 Aug 10;11(8):1440. doi: 10.3390/diagnostics11081440

Table 3.

OVA1 Performance Stratified by Race.

		OVA1 Performance When CA125 Is Low-Risk * by Race
	Menopausal Status	N	Sensitivity (%, n/N)	Specificity (%, n/N)	PPV (%, n/N)	NPV (%, n/N)	LR+	LR−
White/Caucasian	All	1492	64.62%	67.90%	8.40%	97.68%	2.01	0.52
	All	1492	42/65	969/1427	42/500	969/992	2.01	0.52
	Pre	848	54.55%	75.18%	5.53%	98.42%	2.20	0.60
	Pre	848	12/22	621/826	12/217	621/631	2.20	0.60
	Post	644	69.77%	57.90%	10.60%	96.40%	1.66	0.52
	Post	644	30/43	348/601	30/283	348/361	1.66	0.52
Black/African American	All	283	41.67%	79.32%	8.33%	96.79%	2.02	0.74
	All	283	5/12	211/266	5/60	211/218	2.02	0.74
	Pre	195	37.50%	82.07%	8.33%	96.79%	2.09	0.76
	Pre	195	3/8	151/184	3/36	151/156	2.09	0.76
	Post	88	50.00%	73.17%	8.33%	96.77%	1.86	0.68
	Post	88	2/4	60/82	2/24	60/62	1.86	0.68

PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR−, negative likelihood ratio. Cancer prevalence is 4.5% (104/2305). * Low-risk CA125, 67 U/mL for premenopausal subjects; 35 U/mL for postmenopausal or unknown subjects.